| Title |
Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
|
|---|---|
| Published in |
Drugs, December 2016
|
| DOI | 10.1007/s40265-016-0666-0 |
| Pubmed ID | |
| Authors |
Karly P. Garnock-Jones |
| Abstract |
Intravenous dalbavancin (Dalvance(®), Xydalba(®)), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and tolerability as a single-dose regimen in the treatment of adult patients with ABSSSI. Single-dose dalbavancin is an effective and generally well tolerated treatment option for adults with ABSSSI, with noninferior efficacy to the two-dose dalbavancin regimen with regard to early clinical response (at 48-72 h) and low rates of adverse events. Clinical success rates at days 14 and 28 also did not significantly differ between the single- and two-dose dalbavancin regimens; neither did clinical success rates at day 14 when analysed by baseline pathogen. It has a broad spectrum of activity against common ABSSSI-related pathogens, and a favourable pharmacokinetic profile allowing for the convenience of single-dose administration. Thus, dalbavancin presents a promising alternative to conventional antibacterials for the treatment of ABSSSI in adult patients. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 17% |
| United States | 1 | 17% |
| United Kingdom | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 50% |
| Members of the public | 3 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 38% |
| Student > Doctoral Student | 4 | 14% |
| Student > Postgraduate | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Researcher | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 2 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 13 | 45% |
| Medicine and Dentistry | 6 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 14% |
| Psychology | 1 | 3% |
| Immunology and Microbiology | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2023.
All research outputs
#8,380,858
of 25,040,629 outputs
Outputs from Drugs
#1,483
of 3,465 outputs
Outputs of similar age
#135,191
of 406,354 outputs
Outputs of similar age from Drugs
#18
of 31 outputs
Altmetric has tracked 25,040,629 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,465 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 406,354 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.